Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

INIO – Innio NV

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=INIO#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
INIO — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

7.36

Margin Of Safety %

-29

Put/Call OI Ratio

0.29

EPS Next Q Diff

0.09

EPS Last/This Y

0.17

EPS This/Next Y

0.43

Price

27.35

Target Price

38.7

Analyst Recom

1.5

Performance Q

Upside

N/A

Beta

Ticker: INIO




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14INIO30.860.150.872292
2026-07-15INIO30.260.161.672313
2026-07-16INIO28.030.161.642317
2026-07-17INIO27.820.170.042360
2026-07-20INIO27.490.150.002437
2026-07-21INIO30.370.150.022443
2026-07-22INIO27.430.112.213186
2026-07-23INIO28.010.150.253340
2026-07-24INIO26.260.150.293349
2026-07-27INIO26.890.150.873362
2026-07-28INIO26.240.1614.233407
2026-07-29INIO21.70.162.323419
2026-07-30INIO24.350.280.133748
2026-07-31INIO24.440.270.133952
2026-08-03INIO24.870.270.293952
2026-08-04INIO27.330.270.863986
2026-08-05INIO26.090.291.004075
2026-08-06INIO25.960.290.004052
2026-08-07INIO27.360.290.644057
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-14INIO30.81- - -
2026-07-15INIO30.16- - -
2026-07-16INIO28.01- - -
2026-07-17INIO27.75- - -
2026-07-20INIO27.50- - -
2026-07-21INIO30.33- - -
2026-07-22INIO27.43- - -
2026-07-23INIO28.00- - -
2026-07-24INIO26.27- - -
2026-07-27INIO26.91- - -
2026-07-28INIO26.23- - -
2026-07-29INIO21.77- - -
2026-07-30INIO24.36- - -
2026-07-31INIO24.45- - 0.32
2026-08-03INIO24.90- - 0.32
2026-08-04INIO24.90- - 0.32
2026-08-05INIO26.09- - 0.32
2026-08-06INIO25.97- - 0.32
2026-08-07INIO27.35- - 0.36
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




16 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-14INIO-13.770.627.83
2026-07-15INIO-13.770.627.83
2026-07-16INIO-13.770.627.83
2026-07-17INIO-13.770.627.83
2026-07-20INIO-13.770.647.83
2026-07-21INIO-13.770.647.83
2026-07-22INIO-13.770.647.83
2026-07-23INIO-13.770.647.83
2026-07-24INIO-13.770.647.83
2026-07-27INIO-13.770.937.36
2026-07-28INIO-13.770.937.36
2026-07-29INIO-13.770.937.36
2026-07-30INIO-13.770.937.36
2026-07-31INIO-13.770.937.36
2026-08-03INIO-13.771.067.36
2026-08-04INIO-13.771.067.36
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
16 items Current Page1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=INIO 589 360 ]

Last Quarter Act. EPS

0.08

Avg. EPS Est. Current Quarter

0.11

Avg. EPS Est. Next Quarter

0.17

Insider Transactions

-13.77

Institutional Transactions

1.06

Beta

Average Sales Estimate Current Quarter

1040

Average Sales Estimate Next Quarter

1228

Fair Value

19.3

Quality Score

58

Growth Score

Sentiment Score

91

Actual DrawDown %

36.3

Max Drawdown 5-Year %

Target Price

38.7

P/E

Forward P/E

PEG

P/S

P/B

98.05

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

0.36

EPS Next Y. (Est.)

0.79

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

Relative Volume

1.03

Return on Equity vs Sector %

4

Return on Equity vs Industry %

-6.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=INIO 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=INIO 589 450 ]
INIO — P/E HistoricalSpecialty Industrial Machinery
INNIO N.V.
Sector: Industrials
Industry: Specialty Industrial Machinery
Employees: 5467
Innio N.V., through its subsidiaries, provides power generation equipment and services under the Jenbacher and Waukesha brands. It operates in two segments, Equipment and Services. The Equipment segment designs, manufactures, and sells new engines, product-related equipment, and related solutions for data center, power solutions, and compression end-markets. The Services segment provides aftermarket services through an engine's lifecycle, including service agreements, spare parts, overhauls, remanufacturing of engines and components, digital solutions, and service-related activities, as well as maintenance and replacement of parts. It also operates Myplant, an AI-enabled fleet management platform. Th company operates in Germany, rest of Europe, the United States, rest of North America, and internationally. Innio N.V. was founded in 2018 and is headquartered in Munich, Germany. Innio N.V. operates as a subsidiary of AI Alpine (Luxembourg) S.à r.l.
INIO

Latest News

Caricamento notizie per INIO
stock quote shares INIO – Innio NV Stock Price stock today
news today INIO – Innio NV stock forecast ,stock prediction 2023 2024 2025
marketwatch INIO – Innio NV yahoo finance google finance
stock history INIO – Innio NV invest stock market
stock prices INIO premarket after hours
ticker INIO fair value insiders trading

EVO – Evotec SE

EVO — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.01

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-0.77

EPS This/Next Y

0.77

Price

2

Target Price

3.01

Analyst Recom

2.2

Performance Q

-34.43

Upside

-1,202.5%

Beta

1.93

Ticker: EVO




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14EVO2.13N/AN/A0
2026-07-15EVO2.01N/AN/A0
2026-07-16EVO1.97N/AN/A0
2026-07-17EVO1.96N/AN/A0
2026-07-20EVO1.98N/AN/A0
2026-07-21EVO2N/AN/A0
2026-07-22EVO1.96N/AN/A0
2026-07-23EVO1.95N/AN/A0
2026-07-24EVO1.94N/AN/A0
2026-07-27EVO1.93N/AN/A0
2026-07-28EVO1.9699N/AN/A0
2026-07-29EVO1.94N/AN/A0
2026-07-30EVO1.94N/AN/A0
2026-07-31EVO1.925N/AN/A0
2026-08-03EVO1.95N/AN/A0
2026-08-04EVO1.95N/AN/A0
2026-08-05EVO1.98N/AN/A0
2026-08-06EVO1.94N/AN/A0
2026-08-07EVO2N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-14EVO2.14- 124.6-0.70
2026-07-15EVO2.01- 107.9-0.70
2026-07-16EVO1.97- 103.2-0.70
2026-07-17EVO1.96- 102.5-0.70
2026-07-20EVO1.99- 101.3-1.10
2026-07-21EVO2.00- 104.1-1.10
2026-07-22EVO1.95- 105.9-1.10
2026-07-23EVO1.95- 103.4-1.10
2026-07-24EVO1.94- 104.5-1.10
2026-07-27EVO1.92- 105.2-1.10
2026-07-28EVO1.97- 101.8-1.10
2026-07-29EVO1.94- 106.0-1.10
2026-07-30EVO1.95- 104.9-1.10
2026-07-31EVO1.92- 105.7-1.10
2026-08-03EVO1.96- 102.7-1.10
2026-08-04EVO1.96- 102.7-1.10
2026-08-05EVO1.98- 102.5-1.10
2026-08-06EVO1.94- 106.0-1.10
2026-08-07EVO2.00- 99.3-1.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-14EVO0.00-27.650.02
2026-07-15EVO0.00-27.650.02
2026-07-16EVO0.00-27.650.02
2026-07-17EVO0.00-27.650.02
2026-07-20EVO0.00-25.170.02
2026-07-21EVO0.00-25.170.02
2026-07-22EVO0.00-25.170.02
2026-07-23EVO0.00-25.170.02
2026-07-24EVO0.00-25.170.02
2026-07-27EVO0.00-13.310.01
2026-07-28EVO0.00-13.310.01
2026-07-29EVO0.00-13.310.01
2026-07-30EVO0.00-13.310.01
2026-07-31EVO0.00-13.310.01
2026-08-03EVO0.00-13.200.01
2026-08-04EVO0.00-13.200.01
2026-08-05EVO0.00-13.200.01
2026-08-06EVO0.00-13.200.01
2026-08-07EVO0.00-13.200.01
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.04

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

Institutional Transactions

-13.2

Beta

1.93

Average Sales Estimate Current Quarter

175

Average Sales Estimate Next Quarter

146

Fair Value

Quality Score

33

Growth Score

33

Sentiment Score

85

Actual DrawDown %

92.5

Max Drawdown 5-Year %

-92.8

Target Price

3.01

P/E

Forward P/E

PEG

P/S

0.82

P/B

0.88

P/Free Cash Flow

EPS

-0.63

Average EPS Est. Cur. Y​

-1.1

EPS Next Y. (Est.)

-0.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-26.08

Relative Volume

0.87

Return on Equity vs Sector %

-55

Return on Equity vs Industry %

-34.5

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.41

EBIT Estimation

99.3
EVO Healthcare
$2.00
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
0/20
Pullback
21/25
Volume
7/15
Valuation
12/20
TP/AR
1/10
Options
0/10
RSI
37
Range 1M
8.8%
Sup Dist
3.8%
🚀
Momentum Growth
Ride accelerating trends
N/A
8 /100
WEAK
Momentum
0/25
Growth
8/30
Estimates
0/20
Inst/Vol
0/15
Options
0/10
EPS Yr
-78.8%
EPS NY
76.2%
52W%
3.6%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +50.5% upside
Quality
2/30
Valuation
12/30
Growth
6/25
Stability
4/10
LT Trend
1/5
Upside
+50.5%
Quality
33
EVO — P/E HistoricalDrug Manufacturers - Specialty & Generic
Evotec SE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 4526
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
EVO

Latest News

Caricamento notizie per EVO
stock quote shares EVO – Evotec SE Stock Price stock today
news today EVO – Evotec SE stock forecast ,stock prediction 2023 2024 2025
marketwatch EVO – Evotec SE yahoo finance google finance
stock history EVO – Evotec SE invest stock market
stock prices EVO premarket after hours
ticker EVO fair value insiders trading

VJET – Voxeljet AG ADR

VJET — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.11

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.19

Price

1

Target Price

2.67

Analyst Recom

1

Performance Q

-45.29

Upside

N/A

Beta

1.07

Ticker: VJET




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14VJET0.6401N/AN/A0
2026-07-15VJET0.6401N/AN/A0
2026-07-16VJET0.6401N/AN/A0
2026-07-17VJET0.6401N/AN/A0
2026-07-20VJET0.6401N/AN/A0
2026-07-21VJET0.6401N/AN/A0
2026-07-22VJET0.6401N/AN/A0
2026-07-23VJET0.6401N/AN/A0
2026-07-24VJET0.6401N/AN/A0
2026-07-27VJET0.6401N/AN/A0
2026-07-28VJET0.6401N/AN/A0
2026-07-29VJET0.6401N/AN/A0
2026-07-30VJET0.6401N/AN/A0
2026-07-31VJET0.6401N/AN/A0
2026-08-03VJET0.6401N/AN/A0
2026-08-04VJET0.6401N/AN/A0
2026-08-05VJET0.6401N/AN/A0
2026-08-07VJET0.6401N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




No data found




No data found

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

-0.3

Insider Transactions

Institutional Transactions

80.2

Beta

1.07

Average Sales Estimate Current Quarter

7

Average Sales Estimate Next Quarter

13

Fair Value

Quality Score

32

Growth Score

75

Sentiment Score

83

Actual DrawDown %

97.5

Max Drawdown 5-Year %

-98.7

Target Price

2.67

P/E

Forward P/E

PEG

P/S

0.18

P/B

0.38

P/Free Cash Flow

EPS

-1.2

Average EPS Est. Cur. Y​

-1.62

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-34.59

Relative Volume

Return on Equity vs Sector %

-119.2

Return on Equity vs Industry %

-106.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

VJET — P/E HistoricalComputer Hardware
VJET

Latest News

Caricamento notizie per VJET
stock quote shares VJET – Voxeljet AG ADR Stock Price stock today
news today VJET – Voxeljet AG ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch VJET – Voxeljet AG ADR yahoo finance google finance
stock history VJET – Voxeljet AG ADR invest stock market
stock prices VJET premarket after hours
ticker VJET fair value insiders trading

IMTX – Immatics N.V

IMTX — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

4.5

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

0.01

EPS Last/This Y

-0.05

EPS This/Next Y

Price

9.63

Target Price

17.65

Analyst Recom

1

Performance Q

-13.38

Upside

-365.4%

Beta

1.33

Ticker: IMTX




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14IMTX9.343.970.671714
2026-07-15IMTX9.463.973.331716
2026-07-16IMTX9.44.004.001726
2026-07-17IMTX9.614.141.301779
2026-07-20IMTX9.210.390.00318
2026-07-21IMTX9.390.330.00356
2026-07-22IMTX9.180.330.00356
2026-07-23IMTX9.280.330.00356
2026-07-24IMTX9.090.330.00356
2026-07-27IMTX8.630.330.00356
2026-07-28IMTX8.740.330.00356
2026-07-29IMTX9.010.33999.99357
2026-07-30IMTX9.20.340.00358
2026-07-31IMTX8.660.33999.99359
2026-08-03IMTX9.020.34999.99360
2026-08-04IMTX9.350.34999.99360
2026-08-05IMTX9.780.34999.99360
2026-08-07IMTX9.640.390.00373
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-14IMTX9.3528.7- -1.94
2026-07-15IMTX9.4628.7- -1.94
2026-07-16IMTX9.4128.7- -1.94
2026-07-17IMTX9.6328.7- -1.94
2026-07-20IMTX9.2428.7- -1.94
2026-07-21IMTX9.3828.7- -1.94
2026-07-22IMTX9.1728.7- -1.94
2026-07-23IMTX9.2928.7- -1.94
2026-07-24IMTX9.0928.7- -1.94
2026-07-27IMTX8.6228.7- -1.94
2026-07-28IMTX8.7328.7- -1.94
2026-07-29IMTX9.0028.7- -1.94
2026-07-30IMTX9.2128.7- -1.94
2026-07-31IMTX8.6728.7- -1.94
2026-08-03IMTX9.0228.7- -1.94
2026-08-04IMTX9.0228.7- -1.94
2026-08-05IMTX9.7828.7- -1.94
2026-08-06IMTX9.4228.7- -1.94
2026-08-07IMTX9.6329.8- -1.90
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-14IMTX0.005.334.82
2026-07-15IMTX0.005.334.82
2026-07-16IMTX0.005.334.82
2026-07-17IMTX0.005.334.82
2026-07-20IMTX0.005.224.82
2026-07-21IMTX0.005.224.82
2026-07-22IMTX0.005.224.82
2026-07-23IMTX0.005.224.82
2026-07-24IMTX0.005.224.82
2026-07-27IMTX0.005.184.50
2026-07-28IMTX0.005.184.50
2026-07-29IMTX0.005.184.50
2026-07-30IMTX0.005.184.50
2026-07-31IMTX0.005.184.50
2026-08-03IMTX0.00-0.814.50
2026-08-04IMTX0.00-0.814.50
2026-08-05IMTX0.00-0.814.50
2026-08-06IMTX0.00-0.814.50
2026-08-07IMTX0.00-0.814.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.5

Avg. EPS Est. Current Quarter

-0.48

Avg. EPS Est. Next Quarter

-0.49

Insider Transactions

Institutional Transactions

-0.81

Beta

1.33

Average Sales Estimate Current Quarter

12

Average Sales Estimate Next Quarter

11

Fair Value

Quality Score

29

Growth Score

32

Sentiment Score

91

Actual DrawDown %

40.9

Max Drawdown 5-Year %

-77.4

Target Price

17.65

P/E

Forward P/E

PEG

P/S

29.86

P/B

2.51

P/Free Cash Flow

EPS

-1.97

Average EPS Est. Cur. Y​

-1.9

EPS Next Y. (Est.)

-1.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-572.25

Relative Volume

0.61

Return on Equity vs Sector %

-74.4

Return on Equity vs Industry %

-58.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

IMTX Healthcare
$9.65
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
2/20
Pullback
11/25
Volume
9/15
Valuation
10/20
TP/AR
2/10
Options
7/10
RSI
53.4
Range 1M
51.7%
Sup Dist
4.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
15 /100
WEAK
Momentum
2/25
Growth
4/30
Estimates
0/20
Inst/Vol
1/15
Options
8/10
EPS Yr
-4.8%
EPS NY
-0.1%
52W%
61.5%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +82.9% upside
Quality
2/30
Valuation
14/30
Growth
0/25
Stability
7/10
LT Trend
0/5
Upside
+82.9%
Quality
29
IMTX — P/E HistoricalBiotechnology
Immatics N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 678
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX

Latest News

Caricamento notizie per IMTX
stock quote shares IMTX – Immatics N.V Stock Price stock today
news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch IMTX – Immatics N.V yahoo finance google finance
stock history IMTX – Immatics N.V invest stock market
stock prices IMTX premarket after hours
ticker IMTX fair value insiders trading

FMS – Fresenius Medical Care AG ADR

FMS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.5

Margin Of Safety %

-1

Put/Call OI Ratio

0.96

EPS Next Q Diff

-0.01

EPS Last/This Y

0.18

EPS This/Next Y

1.02

Price

24.28

Target Price

23.61

Analyst Recom

3.26

Performance Q

Upside

3.9%

Beta

0.74

Ticker: FMS




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14FMS24.140.490.004205
2026-07-15FMS24.070.490.104205
2026-07-16FMS24.10.50999.994197
2026-07-17FMS24.10.500.174197
2026-07-20FMS24.080.500.174197
2026-07-21FMS24.691.782.00955
2026-07-22FMS24.331.792.00957
2026-07-23FMS24.461.800.00959
2026-07-24FMS24.61.790.00961
2026-07-27FMS24.891.63999.99909
2026-07-28FMS24.761.63999.99909
2026-07-29FMS24.861.63999.99909
2026-07-30FMS25.711.680.00923
2026-07-31FMS25.671.680.00923
2026-08-03FMS25.261.641.13930
2026-08-04FMS24.021.640.10946
2026-08-05FMS23.890.97999.991253
2026-08-07FMS24.270.960.001251
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-14FMS24.158.5-109.22.55
2026-07-15FMS24.088.5-99.92.55
2026-07-16FMS24.108.5-95.22.55
2026-07-17FMS24.118.5-97.52.45
2026-07-20FMS24.088.5-101.52.45
2026-07-21FMS24.688.5-72.92.45
2026-07-22FMS24.339.8-119.82.46
2026-07-23FMS24.469.8-95.92.46
2026-07-24FMS24.599.8-97.22.46
2026-07-27FMS24.899.8-87.72.46
2026-07-28FMS24.759.8-107.72.46
2026-07-29FMS24.879.8-95.02.46
2026-07-30FMS25.729.8-63.42.46
2026-07-31FMS25.679.8-109.82.59
2026-08-03FMS25.279.8-129.22.59
2026-08-04FMS25.279.8-129.22.59
2026-08-05FMS23.909.8-112.92.83
2026-08-06FMS24.109.8-98.32.83
2026-08-07FMS24.280.0-148.72.12
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-14FMS0-1.920.60
2026-07-15FMS0-1.920.60
2026-07-16FMS0-1.920.60
2026-07-17FMS0-1.920.60
2026-07-20FMS0-1.940.60
2026-07-21FMS0-1.940.60
2026-07-22FMS0-1.940.60
2026-07-23FMS0-1.940.60
2026-07-24FMS0-1.940.60
2026-07-27FMS0-1.960.55
2026-07-28FMS0-1.960.55
2026-07-29FMS0-1.960.55
2026-07-30FMS0-1.960.55
2026-07-31FMS0-1.960.55
2026-08-03FMS0-2.030.55
2026-08-04FMS0-2.030.55
2026-08-05FMS0-2.030.55
2026-08-06FMS0-2.030
2026-08-07FMS0-2.030.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.66

Avg. EPS Est. Current Quarter

0.55

Avg. EPS Est. Next Quarter

0.65

Insider Transactions

Institutional Transactions

-2.03

Beta

0.74

Average Sales Estimate Current Quarter

4955

Average Sales Estimate Next Quarter

5073

Fair Value

24.09

Quality Score

62

Growth Score

60

Sentiment Score

13

Actual DrawDown %

40.6

Max Drawdown 5-Year %

-67.8

Target Price

23.61

P/E

12.52

Forward P/E

9.96

PEG

2.81

P/S

0.57

P/B

0.9

P/Free Cash Flow

6.17

EPS

1.94

Average EPS Est. Cur. Y​

2.12

EPS Next Y. (Est.)

3.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

4.82

Relative Volume

1.24

Return on Equity vs Sector %

-19.9

Return on Equity vs Industry %

-95

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.44

EBIT Estimation

-148.7
FMS Healthcare
$24.27
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
10/20
Pullback
19/25
Volume
4/15
Valuation
7/20
TP/AR
0/10
Options
4/10
RSI
50.5
Range 1M
28.2%
Sup Dist
1.4%
🚀
Momentum Growth
Ride accelerating trends
N/A
19 /100
WEAK
Momentum
5/25
Growth
3/30
Estimates
4/20
Inst/Vol
2/15
Options
5/10
EPS Yr
-7%
52W%
55.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +33.4% upside
Quality
6/30
Valuation
11/30
Growth
3/25
Stability
3/10
LT Trend
3/5
Upside
+33.4%
Quality
62
MoS
-1%
FMS — P/E HistoricalMedical Care Facilities
Fresenius Medical Care AG
Sector: Healthcare
Industry: Medical Care Facilities
Employees: 107226
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
FMS

Latest News

Caricamento notizie per FMS
stock quote shares FMS – Fresenius Medical Care AG ADR Stock Price stock today
news today FMS – Fresenius Medical Care AG ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch FMS – Fresenius Medical Care AG ADR yahoo finance google finance
stock history FMS – Fresenius Medical Care AG ADR invest stock market
stock prices FMS premarket after hours
ticker FMS fair value insiders trading

FMS – Fresenius Medical Care AG & Co. KGaA

FMS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.5

Margin Of Safety %

-1

Put/Call OI Ratio

0.96

EPS Next Q Diff

-0.01

EPS Last/This Y

0.18

EPS This/Next Y

1.02

Price

24.28

Target Price

23.61

Analyst Recom

3.26

Performance Q

Upside

3.9%

Beta

0.74

Ticker: FMS




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14FMS24.140.490.004205
2026-07-15FMS24.070.490.104205
2026-07-16FMS24.10.50999.994197
2026-07-17FMS24.10.500.174197
2026-07-20FMS24.080.500.174197
2026-07-21FMS24.691.782.00955
2026-07-22FMS24.331.792.00957
2026-07-23FMS24.461.800.00959
2026-07-24FMS24.61.790.00961
2026-07-27FMS24.891.63999.99909
2026-07-28FMS24.761.63999.99909
2026-07-29FMS24.861.63999.99909
2026-07-30FMS25.711.680.00923
2026-07-31FMS25.671.680.00923
2026-08-03FMS25.261.641.13930
2026-08-04FMS24.021.640.10946
2026-08-05FMS23.890.97999.991253
2026-08-07FMS24.270.960.001251
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-14FMS24.158.5-109.22.55
2026-07-15FMS24.088.5-99.92.55
2026-07-16FMS24.108.5-95.22.55
2026-07-17FMS24.118.5-97.52.45
2026-07-20FMS24.088.5-101.52.45
2026-07-21FMS24.688.5-72.92.45
2026-07-22FMS24.339.8-119.82.46
2026-07-23FMS24.469.8-95.92.46
2026-07-24FMS24.599.8-97.22.46
2026-07-27FMS24.899.8-87.72.46
2026-07-28FMS24.759.8-107.72.46
2026-07-29FMS24.879.8-95.02.46
2026-07-30FMS25.729.8-63.42.46
2026-07-31FMS25.679.8-109.82.59
2026-08-03FMS25.279.8-129.22.59
2026-08-04FMS25.279.8-129.22.59
2026-08-05FMS23.909.8-112.92.83
2026-08-06FMS24.109.8-98.32.83
2026-08-07FMS24.280.0-148.72.12
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-14FMS0-1.920.60
2026-07-15FMS0-1.920.60
2026-07-16FMS0-1.920.60
2026-07-17FMS0-1.920.60
2026-07-20FMS0-1.940.60
2026-07-21FMS0-1.940.60
2026-07-22FMS0-1.940.60
2026-07-23FMS0-1.940.60
2026-07-24FMS0-1.940.60
2026-07-27FMS0-1.960.55
2026-07-28FMS0-1.960.55
2026-07-29FMS0-1.960.55
2026-07-30FMS0-1.960.55
2026-07-31FMS0-1.960.55
2026-08-03FMS0-2.030.55
2026-08-04FMS0-2.030.55
2026-08-05FMS0-2.030.55
2026-08-06FMS0-2.030
2026-08-07FMS0-2.030.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.66

Avg. EPS Est. Current Quarter

0.55

Avg. EPS Est. Next Quarter

0.65

Insider Transactions

Institutional Transactions

-2.03

Beta

0.74

Average Sales Estimate Current Quarter

4955

Average Sales Estimate Next Quarter

5073

Fair Value

24.09

Quality Score

62

Growth Score

60

Sentiment Score

13

Actual DrawDown %

40.6

Max Drawdown 5-Year %

-67.8

Target Price

23.61

P/E

12.52

Forward P/E

9.96

PEG

2.81

P/S

0.57

P/B

0.9

P/Free Cash Flow

6.17

EPS

1.94

Average EPS Est. Cur. Y​

2.12

EPS Next Y. (Est.)

3.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

4.82

Relative Volume

1.24

Return on Equity vs Sector %

-19.9

Return on Equity vs Industry %

-95

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.44

EBIT Estimation

-148.7
FMS Healthcare
$24.27
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
10/20
Pullback
19/25
Volume
4/15
Valuation
7/20
TP/AR
0/10
Options
4/10
RSI
50.5
Range 1M
28.2%
Sup Dist
1.4%
🚀
Momentum Growth
Ride accelerating trends
N/A
19 /100
WEAK
Momentum
5/25
Growth
3/30
Estimates
4/20
Inst/Vol
2/15
Options
5/10
EPS Yr
-7%
52W%
55.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +33.4% upside
Quality
6/30
Valuation
11/30
Growth
3/25
Stability
3/10
LT Trend
3/5
Upside
+33.4%
Quality
62
MoS
-1%
FMS — P/E HistoricalMedical Care Facilities
Fresenius Medical Care AG
Sector: Healthcare
Industry: Medical Care Facilities
Employees: 107226
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
FMS

Latest News

Caricamento notizie per FMS
stock quote shares FMS – Fresenius Medical Care AG & Co. KGaA Stock Price stock today
news today FMS – Fresenius Medical Care AG & Co. KGaA stock forecast ,stock prediction 2023 2024 2025
marketwatch FMS – Fresenius Medical Care AG & Co. KGaA yahoo finance google finance
stock history FMS – Fresenius Medical Care AG & Co. KGaA invest stock market
stock prices FMS premarket after hours
ticker FMS fair value insiders trading
No more stocks to show